Primary Site >> Pancreatic Cancer
Gene >> NQO1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: [Mitomycin C and its bioreduction: relevance of NAD(P)H: quinone oxidoreductase activity to mitomycin C-induced DNA damage and cytotoxicity]. PMID: 7685584 |
Ref: Genetic polymorphism of N-acetyltransferases, glutathione S-transferase M1 and NAD(P)H:quinone oxidoreductase in relation to malignant and benign pancreatic disease risk. The International Pancreatic Disease Study Group. PMID: 9696930 |
Ref: Dicumarol inhibition of NADPH:quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism. PMID: 14500388 |
Ref: Treatment of pancreatic cancer cells with dicumarol induces cytotoxicity and oxidative stress. PMID: 15240547 |
Ref: Efficacy of beta-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1. PMID: 15662131 Ref: Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer. PMID: 16003741 |
Ref: Increased levels of NAD(P)H: quinone oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: A potential biomarker of early damage in the pancreas. PMID: 16532285 Ref: 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo. PMID: 16891456 Ref: Mitochondrial production of reactive oxygen species mediate dicumarol-induced cytotoxicity in cancer cells. PMID: 17040906 |
Ref: Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells. PMID: 17455910 Ref: Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone. PMID: 17638905 Ref: Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity. PMID: 17944451 Ref: Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity. PMID: 17999461 |
Ref: NQO1 expression in pancreatic cancer and its potential use as a biomarker. PMID: 18091324 Ref: Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential. PMID: 18264564 |
Ref: Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). PMID: 19877692 |
Ref: Superoxide dismutase and nicotinamide adenine dinucleotide phosphate: quinone oxidoreductase polymorphisms and pancreatic cancer risk. PMID: 20966810 Ref: Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells. PMID: 21156818 Ref: Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of beta-lapachone for pancreatic cancer therapy. PMID: 21224367 |
Ref: NAD(P)H:quinone oxidoreductase 1 (NQO1) localizes to the mitotic spindle in human cells. PMID: 22984577 |
Ref: Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers. PMID: 23836505 |
Ref: Expanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogenesis pathways. PMID: 25870517 Ref: Combinative effects of beta-Lapachone and APO866 on pancreatic cancer cell death through reactive oxygen species production and PARP-1 activation. PMID: 26188110 Ref: beta-Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy as Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy. PMID: 26415823 Ref: Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ss-lapachone. PMID: 26462257 Ref: Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, beta-lapachone. PMID: 26602448 |
Ref: Esculetin induces antiproliferative and apoptotic response in pancreatic cancer cells by directly binding to KEAP1. PMID: 27756327 |
Ref: Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. PMID: 28346693 Ref: Clinicopathological implications of NQO1 overexpression in the prognosis of pancreatic adenocarcinoma. PMID: 28521407 Ref: Targeting NAD(P)H:Quinone Oxidoreductase (NQO1) in Pancreatic Cancer. PMID: 28639725 Ref: The NQO1 bioactivatable drug, beta-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism. PMID: 28916726 |
Ref: Design and Synthesis of Novel Reactive Oxygen Species Inducers for the Treatment of Pancreatic Ductal Adenocarcinoma. PMID: 29328656 Ref: Pancreatic Cancer Metabolism: Molecular Mechanisms and Clinical Applications. PMID: 29752600 |